Michael Smurfit
Founder at The K Club Ltd.
Profile
Michael William Joseph Smurfit is the founder of The K Club Ltd.
He currently holds director positions at GAN (UK) Ltd., Uc Davis Graduate School of Management, and Inflection Biosciences Ltd.
In the past, he served as an independent non-executive director at Escher Group Holdings Ltd.
from 2013 to 2016 and at GAN Ltd.
from 2003 to 2023.
Smurfit earned a Master's in Business Administration from UCD Michael Smurfit Graduate School of Business.
Michael Smurfit active positions
Companies | Position | Start |
---|---|---|
Gan (UK) Ltd.
Gan (UK) Ltd. Packaged SoftwareTechnology Services Gan (UK) Ltd. engages in the development and supply of Internet gaming enterprise software-as-a-service solutions. It operates through the Real Money Gaming Operations and Simulated Gaming Operations segments. The company was founded by David McDowell and Kevin O'Neal in 2002 and is headquartered in London, the United Kingdom. | Director/Board Member | 2008-06-24 |
The K Club Ltd.
The K Club Ltd. Hotels/Resorts/Cruise linesConsumer Services The K Club Ltd. owns and operates country clubs, hotels and restaurants. IT specializes in five star accommodation, spa, golf, luxury travel, incentive groups, high end corporate executive meetings, corporate events, golf days, society days, weddings, black tie events, press launches and press events. The company was founded by Michael William Joseph Smurfit in 1991 and is headquartered in Straffan, Ireland. | Founder | - |
Inflection Biosciences Ltd.
Inflection Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Inflection Biosciences Ltd. is an Irish drug development company that focuses on discovering and developing small molecule therapeutics to address major unmet needs in cancer, autoimmune, and inflammatory diseases. Inflection Biosciences is based in Blackrock, IE. The private company's pipeline includes IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML, and multiple myeloma, and the IBL-100 series, which comprises selective pan-PIM kinase inhibitors. The partnered pipeline includes AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. | Director/Board Member | - |
Uc Davis Graduate School of Management | Director/Board Member | - |
Former positions of Michael Smurfit
Companies | Position | End |
---|---|---|
GAN LIMITED | Director/Board Member | 2023-12-30 |
ESCHER GROUP HOLDINGS PLC | Director/Board Member | 2016-09-29 |
Training of Michael Smurfit
UCD Michael Smurfit Graduate School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GAN LIMITED | Technology Services |
Private companies | 4 |
---|---|
The K Club Ltd.
The K Club Ltd. Hotels/Resorts/Cruise linesConsumer Services The K Club Ltd. owns and operates country clubs, hotels and restaurants. IT specializes in five star accommodation, spa, golf, luxury travel, incentive groups, high end corporate executive meetings, corporate events, golf days, society days, weddings, black tie events, press launches and press events. The company was founded by Michael William Joseph Smurfit in 1991 and is headquartered in Straffan, Ireland. | Consumer Services |
Gan (UK) Ltd.
Gan (UK) Ltd. Packaged SoftwareTechnology Services Gan (UK) Ltd. engages in the development and supply of Internet gaming enterprise software-as-a-service solutions. It operates through the Real Money Gaming Operations and Simulated Gaming Operations segments. The company was founded by David McDowell and Kevin O'Neal in 2002 and is headquartered in London, the United Kingdom. | Technology Services |
Escher Group Holdings Ltd.
Escher Group Holdings Ltd. Packaged SoftwareTechnology Services Escher Group Holdings Ltd. engages in the provision of retail and message-based software solutions and services. It develops, markets, sells, and supports enterprise-wide software applications for post office Point of Service automation and distributed network communication. The company was founded on June 7, 2007 and is headquartered in Dublin, Ireland. | Technology Services |
Inflection Biosciences Ltd.
Inflection Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Inflection Biosciences Ltd. is an Irish drug development company that focuses on discovering and developing small molecule therapeutics to address major unmet needs in cancer, autoimmune, and inflammatory diseases. Inflection Biosciences is based in Blackrock, IE. The private company's pipeline includes IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML, and multiple myeloma, and the IBL-100 series, which comprises selective pan-PIM kinase inhibitors. The partnered pipeline includes AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. | Health Technology |
- Stock Market
- Insiders
- Michael Smurfit